-
2026-11-06
GenSci R&D Day 2026: Pioneering Innovation From China to the WorldLearn More
-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2024-08-21
Jintrolong? New Dosage Form of Long-acting Somatropin Injection ApprovedLearn More
-
2024-08-06
Clinical Trial Commencement of GenSci098 Injection ApprovedPreclinical data indicate GenSci098 has the potential to become a new treatment for Thyroid Eye Disease
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More